Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma

Clinical Cancer Research

Volumn 20, Issue 11, 2014, Pages 2862-2872

  Smeltzer, Jacob P ^a   Jones, Jason M ^a   Ziesmer, Steven C ^a   Grote, Deanna M ^a   Xiu, Bing ^b   Ristow, Kay M ^a   Yang, Zhi Zhang ^a   Nowakowski, Grzegorz S ^a   Feldman, Andrew L ^a   Cerhan, James R ^a   Novak, Anne J ^a   Ansell, Stephen M ^a  

^a MAYO CLINIC   (United States)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CD14 ANTIGEN; CD68 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; GLYCOPROTEIN P 15095; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CD14+ FOLLICULAR DENDRITIC CELL; CELL COUNT; CELL POPULATION; CELL TYPE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLICULAR DENDRITIC CELL; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PD1+ T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; AGED; CELL TRANSFORMATION; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; CELL TRANSFORMATION, NEOPLASTIC; DENDRITIC CELLS, FOLLICULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROPORTIONAL HAZARDS MODELS; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84901794219     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2367     Document Type: Article

References (44)

1. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165-9.
2. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587-94. (Pubitemid 27167397)
3. Gine E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006;17: 1539-45. (Pubitemid 44542041)
4. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25: 2426-33. (Pubitemid 47007616)
5. Acker B, Hoppe RT, Colby TV, Cox RS, Kaplan HS, Rosenberg SA. Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1983;1:11-6. (Pubitemid 13066136)
6. Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PMV, Stathis A, et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 2012;157:188-96.
7. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470-80. (Pubitemid 17183570)
8. Morley NJ, Evans LS, Goepel J, Hancock BW. Transformed follicular lymphoma: the 25-year experience of a UK provincial lymphoma treatment centre. Oncol Rep 2008;20:953-6.
9. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz- Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65. (Pubitemid 39166497)
10. Yang ZZ, Ansell SM. The tumor microenvironment in follicular lymphoma. Clin Adv Hematol Oncol 2012;10:810-8.
11. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351: 2159- 69.
12. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957- 64.
13. Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009;27:1470-6.
14. + cells and location of forkhead box protein P3- positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052-9.
15. Richendollar BG, Pohlman B, Elson P, Hsi ED. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 2011;42:552-7.
16. + T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007;13:388-97.
17. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010;115:289-95.
18. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74. (Pubitemid 41291735)
19. Canioni D, Salles G,Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-6. (Pubitemid 351171697)
20. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25:2546-53. (Pubitemid 47041228)
21. +HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010;12:631-44.
22. Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004;11:161-7. (Pubitemid 38090671)
23. +HLA-DRlow/- monocytes in prostate cancer. Prostate 2010;70:443-55.
24. +HLA-DR(low)/- monocytes in B-cell non- Hodgkin lymphoma. Blood 2011;117:872-81.
25. Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1 -positive, regulatory, cytotoxic, and Helper T cells and macrophages. Clin Cancer Res 2010;16:637-50.
26. Glass G, Papin JA, Mandell JW. SIMPLE: a sequential immunoperoxidase labeling and erasing method. J Histochem Cytochem 2009;57: 899-905.
27. Schriever F, Freedman AS, Freeman G, Messner E, Lee G, Daley J, et al. Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med 1989;169:2043-58. (Pubitemid 19162965)
28. Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR,Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo- Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 2013;31:3272-8.
29. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-26. (Pubitemid 37323235)
30. Crotty S. Follicular Helper CD4 T cells (TFH). Ann Rev Immunol 2011; 29:621-63.
31. Ame-Thomas P, Le Priol J, Yssel H, Caron G, Pangault C, Jean R, et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 2012;26:1053-63.
32. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012;122:1271-82.
33. Jersmann HPA. Time to abandon dogma: CD14 is expressed by nonmyeloid lineage cells. Immunol Cell Biol 2005;83:462- 7.
34. Naeim F, Rao PN, Grody WW. Hematopathology: morphology, immunophenotype, cytogenetics, and molecular approaches. 1st ed. Amsterdam, UK: Academic press-Elsevier; 2008. p. 297-372.
35. Kridel R, Tan K, Al-Tourah AJ, Moccia AA, Scott DW, Slack GW, et al. Tumor-associated macrophages predict outcome in follicular lymphoma. ASH Annual Meeting Abstracts 2012;120:682.
36. Petrasch S, Perez-alvarez C, Schmitz J, Kosco M, Brittinger G. Antigenic phenotyping of human follicular dendritic cells isolated from nonmalignant and malignant lymphatic tissue. Eur J Immunol 1990;20:1013-8. (Pubitemid 20206051)
37. Jin MK, Hoster E, Dreyling M, Unterhalt M, Hiddemann W, Klapper W. Follicular dendritic cells in follicular lymphoma and types of non- Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome. Histopathology 2011;58:586-92.
38. Park CS, Choi YS. How do follicular dendritic cells interact intimately with B cells in the germinal centre? Immunology 2005; 114:2- 10.
39. Goval JJ, Thielen C, Bourguignon C, Greimers R, Dejardin E, Choi YS, et al. The prevention of spontaneous apoptosis of follicular lymphoma B cells by a follicular dendritic cell line: involvement of caspase-3, caspase-8 and c-FLIP. Haematologica 2008;93:1169-77.
40. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947-53. (Pubitemid 40525197)
41. Thompson RH, Kuntz SM, Leibovich BC, Dong H, LohseCM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66: 3381-5.
42. + T cell density and architectural patterns predict overall survival and risk of transformation in uniformly treated patients with follicular lymphoma. Blood 2008;112:2815.
43. Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE,Wessels LA, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25: 390- 8.
44. Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW,et al. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol 2010;21:1196-202.